Related Experiment Video

Updated: Aug 9, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

802

Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative

Yong Weon Yi1

  • 1Department of Biochemistry, College of Medicine, Dankook University, Cheonan-si 31116, Chungcheongnam-do, Republic of Korea.

International Journal of Molecular Sciences
|February 25, 2023
PubMed

Insights

Extracellular vesicles (EVs) from cancer cells drive drug resistance. This review examines how triple-negative breast cancer EVs (TNBC-EVs) promote resistance and explores strategies to overcome this challenge.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Anticancer drug resistance poses a major challenge in cancer therapy.
  • Extracellular vesicles (EVs) are increasingly recognized as key mediators of drug resistance, tumor progression, and metastasis.
  • Triple-negative breast cancer (TNBC) presents unique therapeutic challenges, with EVs potentially playing a significant role in its resistance mechanisms.

Purpose of the Study:

  • To review the current understanding of how EVs derived from triple-negative breast cancer cells (TNBC-EVs) contribute to anticancer drug resistance.
  • To analyze the molecular cargo and mechanisms by which TNBC-EVs confer drug resistance.
  • To discuss potential therapeutic strategies to overcome TNBC-EV-mediated drug resistance.

Main Methods:

  • Literature review of studies investigating EVs in cancer drug resistance.
  • Analysis of research on TNBC cell-derived EVs and their cargo.
  • Synthesis of findings on mechanisms of EV-mediated drug resistance.

Main Results:

  • TNBC-EVs transfer various biomolecules (proteins, nucleic acids, lipids) that induce drug resistance in recipient cancer cells.
  • Specific molecular components within TNBC-EVs have been identified as critical effectors of resistance.
  • EVs can alter the tumor microenvironment, further promoting resistance and metastasis.

Conclusions:

  • TNBC-EVs are significant contributors to therapeutic resistance in triple-negative breast cancer.
  • Targeting TNBC-EVs or their cargo represents a promising therapeutic avenue.
  • Further research into EV-mediated drug resistance mechanisms is crucial for developing effective cancer treatments.
Keywords:
anticancer therapeuticsdrug resistanceexosomesextracellular vesiclestriple-negative breast cancertumor cell-derived extracellular vesicles

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.6K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K